HRP20250390T1 - Režim doziranja koji sadrži antagonist hormona za oslobađanje gonadotropina za liječenje mioma maternice i smanjenje menstrualnog gubitka krvi - Google Patents
Režim doziranja koji sadrži antagonist hormona za oslobađanje gonadotropina za liječenje mioma maternice i smanjenje menstrualnog gubitka krvi Download PDFInfo
- Publication number
- HRP20250390T1 HRP20250390T1 HRP20250390TT HRP20250390T HRP20250390T1 HR P20250390 T1 HRP20250390 T1 HR P20250390T1 HR P20250390T T HRP20250390T T HR P20250390TT HR P20250390 T HRP20250390 T HR P20250390T HR P20250390 T1 HRP20250390 T1 HR P20250390T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- patient
- per day
- use according
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762515232P | 2017-06-05 | 2017-06-05 | |
| PCT/EP2018/064767 WO2018224497A1 (en) | 2017-06-05 | 2018-06-05 | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| EP18731976.9A EP3634419B1 (en) | 2017-06-05 | 2018-06-05 | Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20250390T1 true HRP20250390T1 (hr) | 2025-05-23 |
Family
ID=62636157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20250390TT HRP20250390T1 (hr) | 2017-06-05 | 2018-06-05 | Režim doziranja koji sadrži antagonist hormona za oslobađanje gonadotropina za liječenje mioma maternice i smanjenje menstrualnog gubitka krvi |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11759464B2 (enExample) |
| EP (2) | EP4509173A3 (enExample) |
| JP (2) | JP7292566B2 (enExample) |
| KR (1) | KR102884301B1 (enExample) |
| CN (1) | CN110996957A (enExample) |
| AU (2) | AU2018280741B2 (enExample) |
| CA (1) | CA3066188A1 (enExample) |
| DK (1) | DK3634419T3 (enExample) |
| EA (1) | EA201992812A1 (enExample) |
| ES (1) | ES3018358T3 (enExample) |
| FI (1) | FI3634419T3 (enExample) |
| HR (1) | HRP20250390T1 (enExample) |
| HU (1) | HUE070907T2 (enExample) |
| MX (2) | MX2019014482A (enExample) |
| PL (1) | PL3634419T3 (enExample) |
| PT (1) | PT3634419T (enExample) |
| SG (1) | SG11201911599XA (enExample) |
| WO (1) | WO2018224497A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL241595B2 (en) | 2013-03-15 | 2025-10-01 | Abbvie Inc | Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids |
| EP3634418A1 (en) | 2017-06-05 | 2020-04-15 | ObsEva S.A. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| US11759464B2 (en) | 2017-06-05 | 2023-09-19 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| AU2018419533A1 (en) | 2018-04-19 | 2020-11-12 | Abbvie Inc. | Methods of treating heavy menstrual bleeding |
| JP2021532160A (ja) * | 2018-08-01 | 2021-11-25 | アッヴィ・インコーポレイテッド | エラゴリックスに関する投与計画 |
| WO2020089190A2 (en) | 2018-10-29 | 2020-05-07 | ObsEva S.A. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| KR20210100623A (ko) * | 2018-11-07 | 2021-08-17 | 옵스에파 에스에이 | 에스트로겐-의존성 장애의 치료를 위한 조성물 및 방법 |
| US20220288154A1 (en) * | 2019-08-08 | 2022-09-15 | ObsEva S.A. | Gnrh antagonists for the treatment of estrogen-dependent disorders |
| KR20220061120A (ko) * | 2019-08-08 | 2022-05-12 | 옵스에파 에스에이 | 에스트로겐-의존성 장애 치료용 조성물 및 방법 |
| KR20210155350A (ko) | 2020-06-15 | 2021-12-22 | 한상왕 | 녹차 추출물 및 비타민 d3를 유효성분으로 포함하는 자궁근종 개선용 조성물 |
| CN115232144B (zh) * | 2021-04-22 | 2024-04-02 | 长春金赛药业有限责任公司 | 含氮稠环类衍生物、药物组合物及其制备方法和应用 |
| KR102738115B1 (ko) | 2024-03-25 | 2024-12-05 | 한상왕 | 자궁근종 예방, 개선 또는 치료용 약학 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7109171B2 (en) | 2000-02-28 | 2006-09-19 | Praecis Pharmaceuticals Inc. | Methods for treating FSH related conditions with GnRH antagonists |
| PT1939204E (pt) * | 2005-10-19 | 2013-03-14 | Kissei Pharmaceutical | Derivado heterocíclico fundido, composição medicinal contendo o mesmo, e sua utilização medicinal |
| EP2535342B1 (en) * | 2010-02-10 | 2014-08-06 | Kissei Pharmaceutical Co., Ltd. | Salt of fused heterocyclic derivative and crystal thereof |
| JP6268093B2 (ja) | 2012-09-14 | 2018-01-24 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
| IL241595B2 (en) | 2013-03-15 | 2025-10-01 | Abbvie Inc | Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids |
| AU2017309015B2 (en) | 2016-08-08 | 2022-09-15 | Kissei Pharmaceutical Co., Ltd. | Administration and dosage of therapeutic agent for endometriosis |
| SMT202200254T1 (it) | 2016-09-30 | 2022-07-21 | Takeda Pharmaceuticals Co | Metodi di trattamento di fibromi uterini ed endometriosi |
| EP3634418A1 (en) | 2017-06-05 | 2020-04-15 | ObsEva S.A. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| US11759464B2 (en) | 2017-06-05 | 2023-09-19 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| KR20210100623A (ko) | 2018-11-07 | 2021-08-17 | 옵스에파 에스에이 | 에스트로겐-의존성 장애의 치료를 위한 조성물 및 방법 |
-
2018
- 2018-06-05 US US16/619,702 patent/US11759464B2/en active Active
- 2018-06-05 MX MX2019014482A patent/MX2019014482A/es unknown
- 2018-06-05 PT PT187319769T patent/PT3634419T/pt unknown
- 2018-06-05 EP EP24221894.9A patent/EP4509173A3/en active Pending
- 2018-06-05 EA EA201992812A patent/EA201992812A1/ru unknown
- 2018-06-05 PL PL18731976.9T patent/PL3634419T3/pl unknown
- 2018-06-05 ES ES18731976T patent/ES3018358T3/es active Active
- 2018-06-05 AU AU2018280741A patent/AU2018280741B2/en active Active
- 2018-06-05 HU HUE18731976A patent/HUE070907T2/hu unknown
- 2018-06-05 FI FIEP18731976.9T patent/FI3634419T3/fi active
- 2018-06-05 EP EP18731976.9A patent/EP3634419B1/en active Active
- 2018-06-05 MX MX2023013582A patent/MX2023013582A/es unknown
- 2018-06-05 CA CA3066188A patent/CA3066188A1/en active Pending
- 2018-06-05 WO PCT/EP2018/064767 patent/WO2018224497A1/en not_active Ceased
- 2018-06-05 CN CN201880050807.2A patent/CN110996957A/zh active Pending
- 2018-06-05 KR KR1020197038980A patent/KR102884301B1/ko active Active
- 2018-06-05 JP JP2019566909A patent/JP7292566B2/ja active Active
- 2018-06-05 DK DK18731976.9T patent/DK3634419T3/da active
- 2018-06-05 SG SG11201911599XA patent/SG11201911599XA/en unknown
- 2018-06-05 HR HRP20250390TT patent/HRP20250390T1/hr unknown
-
2023
- 2023-03-20 JP JP2023043718A patent/JP7485815B2/ja active Active
- 2023-09-11 US US18/244,773 patent/US20240000785A1/en active Pending
-
2024
- 2024-03-14 AU AU2024201694A patent/AU2024201694A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3634419A1 (en) | 2020-04-15 |
| FI3634419T3 (fi) | 2025-05-02 |
| EP4509173A2 (en) | 2025-02-19 |
| HUE070907T2 (hu) | 2025-07-28 |
| AU2018280741B2 (en) | 2023-12-21 |
| ES3018358T3 (es) | 2025-05-16 |
| CA3066188A1 (en) | 2018-12-13 |
| KR20200024797A (ko) | 2020-03-09 |
| AU2024201694A1 (en) | 2024-04-04 |
| JP7292566B2 (ja) | 2023-06-19 |
| US11759464B2 (en) | 2023-09-19 |
| PL3634419T3 (pl) | 2025-06-09 |
| EP3634419B1 (en) | 2025-01-29 |
| KR102884301B1 (ko) | 2025-11-11 |
| DK3634419T3 (da) | 2025-03-31 |
| CN110996957A (zh) | 2020-04-10 |
| EA201992812A1 (ru) | 2020-05-21 |
| MX2023013582A (es) | 2024-04-16 |
| JP2020522525A (ja) | 2020-07-30 |
| JP2023078315A (ja) | 2023-06-06 |
| AU2018280741A1 (en) | 2020-01-30 |
| JP7485815B2 (ja) | 2024-05-16 |
| SG11201911599XA (en) | 2020-01-30 |
| US20240000785A1 (en) | 2024-01-04 |
| EP4509173A3 (en) | 2025-06-04 |
| PT3634419T (pt) | 2025-04-04 |
| MX2019014482A (es) | 2020-08-17 |
| US20200179390A1 (en) | 2020-06-11 |
| WO2018224497A1 (en) | 2018-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20250390T1 (hr) | Režim doziranja koji sadrži antagonist hormona za oslobađanje gonadotropina za liječenje mioma maternice i smanjenje menstrualnog gubitka krvi | |
| HRP20220708T4 (hr) | Postupci liječenja fibroida maternice i endometrioze | |
| JP2023002662A5 (enExample) | ||
| EP2968566A1 (en) | Compositions for use in treating heavy menstrual bleeding and uterine fibroids | |
| TW200831107A (en) | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens | |
| JP2012502988A (ja) | 月経抑制、避妊、およびホルモン補充療法のための製剤、ならびにその投与方法 | |
| US20140200202A1 (en) | Use of estetrol as emergency contraceptive | |
| KR102433001B1 (ko) | 자궁내막증 치료제의 용법·용량 | |
| AU680631B2 (en) | Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy | |
| JPH0735335B2 (ja) | 子宮内膜症の治療薬 | |
| BG66128B1 (bg) | Фармацевтичен състав и използването му за терапевтичен контрол на извънматочна пролиферация на ендометриална тъкан | |
| ES2320662T3 (es) | Hormonoterapia restitutiva y tratamiento para la depresion con dienogest. | |
| Chow et al. | The pharmacological management of intermittent priapismic states. | |
| CN105311137A (zh) | 一种缓解子宫内膜异位症所导致的慢性盆腔痛和痛经的外用中药组合物 | |
| KR20150085512A (ko) | 필요시 피임을 위한 레보노르게스트렐 및 cox 억제제 함유 제약 조성물의 용도 및 적용 요법 | |
| KR100262177B1 (ko) | 동통 처치용 조성물, 동통 처치 방법 및 동통 경감작용 증강조성물 | |
| HRP20231470T1 (hr) | Terapija za infekcije humanim papilomavirusom visokog rizika | |
| US9339542B2 (en) | Hypertension reducing composition | |
| CN108853007B (zh) | 一种治疗功能性子宫出血的凝胶制剂及其用途 | |
| CN102988401B (zh) | 三磷酸腺苷或其可药用盐在制备治疗子宫内膜异位症的药物中的应用 | |
| JP2019507195A5 (enExample) | ||
| JP2017066143A (ja) | 止瀉剤組成物 | |
| JP2016121090A (ja) | 子宮腺筋症患者の子宮出血抑制用医薬 | |
| RU2017127175A (ru) | Новое медицинское применение липоевой кислоты | |
| CN105126085A (zh) | 一种治疗原发性痛经的药物组合物 |